Skip to main content
. 2021 Jun 1;11:683057. doi: 10.3389/fonc.2021.683057

Figure 3.

Figure 3

Analysis was performed in patients with high-grade serous ovarian cancer. (A) Progression-free survival (PFS) and (B) Overall survival (OS) based on the presence of pathogenic variants in HRR and/or TP53 genes. (C) PFS and (D) OS based on the presence of clonal pathogenic variants in HRR and/or TP53 genes. (E) Forest plot of hazard ratios showing the risk of death for patients with HRR and/or TP53 clonal pathogenic variants upon adjustment for clinicopathological parameters. *Statistically significant parameters.